1. A 52-year-old woman with treatment-resistant major depression is started on phenelzine 45 mg/day. Her psychiatrist provides dietary counseling. Three weeks later she presents to the emergency department with a sudden severe occipital headache, BP 218/134 mmHg, heart rate 104 bpm, diaphoresis, and nausea. She reports eating a charcuterie board with aged cheeses and salami at a dinner party two hours earlier. Which of the following most accurately explains the complete pharmacological mechanism of her presentation?

• A) Phenelzine is a selective MAO-B inhibitor that selectively reduces dopamine catabolism in the striatum; the hypertensive crisis reflects dopamine excess from reduced MAO-B activity, and the aged cheese exposure was incidental; tyramine in food does not interact with MAO-B inhibitors because MAO-B does not participate in intestinal tyramine inactivation; her presentation should be attributed to a hypertensive emergency from an unrelated cause.
• B) Phenelzine is a non-selective irreversible MAO inhibitor (inhibiting both MAO-A and MAO-B) -- under normal conditions, dietary tyramine from aged cheese and cured meats is inactivated by intestinal and hepatic MAO-A before reaching the systemic circulation; phenelzine abolishes this first-pass MAO-A inactivation, allowing large amounts of tyramine to enter the systemic circulation; tyramine is taken up into sympathetic nerve terminals via NET, enters vesicles via VMAT2, and displaces stored NE into the synapse by reverse transport through NET; the massive NE release produces the hypertensive crisis; additionally, phenelzine prevents intraneuronal MAO-A from degrading the displaced NE in the terminal cytoplasm, amplifying the effect; treatment is IV phentolamine (alpha-1/alpha-2 antagonist) or nitroprusside for acute BP control.
• C) Phenelzine's hypertensive effect is mediated through serotonin syndrome rather than tyramine-induced NE release -- phenelzine inhibits MAO-A, which metabolizes serotonin; aged cheese contains high concentrations of tryptophan (serotonin precursor); the combination of MAO inhibition and dietary tryptophan loading causes serotonin accumulation at central and peripheral 5-HT receptors producing the serotonin syndrome triad (neuromuscular abnormalities, autonomic instability, altered mental status); treatment is cyproheptadine (5-HT2A antagonist) rather than alpha-adrenergic blockade.
• D) Phenelzine inhibits both MAO-A and MAO-B irreversibly, preventing intestinal and hepatic first-pass degradation of dietary tyramine -- tyramine reaches sympathetic nerve terminals in high concentrations and produces massive NE displacement through its indirect sympathomimetic mechanism (NET uptake, VMAT2 entry, NE displacement, reverse NET transport); simultaneously, phenelzine prevents intraneuronal MAO-A from degrading the excess cytoplasmic NE in the terminal, amplifying and prolonging the NE surge; the clinical presentation (sudden severe headache -- thunderclap, hypertensive emergency, diaphoresis, tachycardia) represents a potentially fatal hypertensive crisis; beta-blockade alone is contraindicated (unopposed alpha-1 vasoconstriction worsens hypertension); phentolamine IV or nicardipine IV is the correct acute management while the irreversible MAOI effect persists for 2-3 weeks.
• E) Phenelzine inhibits MAO and produces its hypertensive effect through a direct mechanism -- phenelzine itself (not tyramine) directly activates alpha-1 adrenergic receptors on vascular smooth muscle after its first-pass bypass of intestinal MAO; the cheese exposure is relevant because fat in aged cheese delays gastric emptying, increasing phenelzine absorption and raising plasma phenelzine concentrations to the threshold for direct alpha-1 activation; dietary fat restriction (not tyramine restriction) is the appropriate preventive strategy.

2. A 34-year-old man with a history of alcohol dependence is started on disulfiram 500 mg/day as part of aversion therapy. He is warned to avoid all alcohol including in foods, mouthwash, and topical products. Which of the following most accurately explains the biochemical mechanism of the disulfiram-ethanol reaction and identifies the specific enzyme involved?

• A) Disulfiram inhibits alcohol dehydrogenase (ADH), preventing the first step of ethanol metabolism (ethanol -> acetaldehyde) -- when ethanol is consumed, it accumulates in the blood without conversion to acetaldehyde; the toxic syndrome results from direct ethanol toxicity at extremely high blood ethanol concentrations; blood acetaldehyde levels are actually lower than normal because disulfiram-inhibited ADH prevents acetaldehyde production.
• B) Disulfiram inhibits dopamine beta-hydroxylase (DBH, which converts dopamine to norepinephrine in sympathetic vesicles) in addition to aldehyde dehydrogenase -- the DBH inhibition depletes NE stores in sympathetic terminals; when ethanol is consumed and produces acetaldehyde (from ADH-mediated conversion), acetaldehyde triggers release from the depleted sympathetic terminals; the disulfiram-ethanol reaction therefore involves both acetaldehyde toxicity and catecholamine depletion, explaining the complex cardiovascular profile (flushing from acetaldehyde vasodilation combined with hypotension from NE depletion rather than reflex tachycardia).
• C) Disulfiram inhibits alcohol dehydrogenase (converting ethanol to acetaldehyde) rather than aldehyde dehydrogenase -- acetaldehyde levels are not elevated; the toxic reaction is from disulfiram itself acting as a direct histamine releaser when it encounters ethanol in the stomach, producing the flushing, headache, nausea, and hypotension of the reaction through mast cell histamine release rather than acetaldehyde accumulation.
• D) Disulfiram irreversibly inhibits aldehyde dehydrogenase (ALDH), the enzyme responsible for oxidizing acetaldehyde (produced from ethanol by alcohol dehydrogenase) to acetate -- ALDH inhibition causes acetaldehyde to accumulate in the blood when ethanol is consumed; acetaldehyde produces the disulfiram-ethanol reaction: intense flushing (from peripheral vasodilation), throbbing headache, nausea and vomiting, tachycardia, hypotension, and dyspnea; additionally, disulfiram inhibits dopamine beta-hydroxylase, reducing NE synthesis in sympathetic terminals, which can contribute to hypotension and explains some of the cardiovascular features; the aversive reaction deters alcohol consumption and can be life-threatening at high ethanol doses.
• E) Disulfiram acts exclusively as a psychological deterrent without any biochemical mechanism -- the disulfiram-ethanol reaction is a nocebo effect produced by the expectation of a negative consequence; randomized controlled trials have shown that the blood acetaldehyde levels measured during the disulfiram-ethanol reaction do not differ from those seen with ethanol alone in patients without disulfiram; disulfiram's therapeutic benefit derives entirely from the cognitive deterrence it provides rather than any actual biochemical interaction with ethanol metabolism.

3. A 19-year-old college student presents to the student health clinic requesting a prescription for methylphenidate, which a friend has been sharing with him for studying. He reports excellent concentration improvement. His evaluation reveals no attention or hyperactivity symptoms in childhood or adulthood. Which of the following most accurately explains the primary mechanism of methylphenidate at catecholaminergic synapses and why this mechanism produces different clinical effects in individuals with ADHD versus neurotypical individuals?

• A) Methylphenidate is a direct dopamine and norepinephrine receptor agonist that activates D1 and alpha-2A receptors in the prefrontal cortex -- in individuals with ADHD, these receptors are underexpressed (D1 and alpha-2A receptor density is reduced by approximately 50% compared to neurotypical individuals), so standard doses produce receptor-level effects equivalent to a much lower functional dose in neurotypical individuals; in neurotypical individuals, the standard ADHD dose produces supraphysiological receptor activation, explaining the enhanced cognition; this receptor density difference provides the biological basis for the clinical paradox of stimulant calming in ADHD.
• B) Methylphenidate blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing reuptake of dopamine and NE from the synapse and increasing their synaptic concentrations in the prefrontal cortex and striatum -- in ADHD, prefrontal cortical catecholamine signaling is tonically deficient (consistent with the delayed cortical maturation model), and methylphenidate restores catecholamine concentrations toward an optimal range that improves prefrontal cortex function (working memory, impulse control, sustained attention) by strengthening D1 and alpha-2A receptor signaling; in neurotypical individuals, baseline catecholamine signaling is already in or near the optimal range, and methylphenidate raises catecholamine concentrations above the optimum, potentially impairing prefrontal function (inverted-U dose-response) while producing subjective stimulant effects from striatal dopamine accumulation; this pharmacological distinction does not confer legal legitimacy on diversion.
• C) Methylphenidate inhibits MAO-A in the prefrontal cortex, preventing intraneuronal NE and dopamine degradation after reuptake -- unlike amphetamine, which releases catecholamines from vesicles, methylphenidate acts entirely postsynaptically by blocking MAO-A; the prefrontal therapeutic effect reflects increased intraneuronal catecholamine availability that slowly diffuses back into the synapse over 4-6 hours; the slower onset of methylphenidate compared to amphetamine reflects the time required for accumulated intraneuronal catecholamines to reach therapeutic synaptic concentrations.
• D) Methylphenidate acts identically to amphetamine, functioning as an indirect sympathomimetic that reverses the direction of DAT and NET transport through phosphorylation of the transporter by PKC, actively pumping dopamine and NE out of the nerve terminal in a calcium-independent non-vesicular manner; this efflux mechanism produces large rapid increases in synaptic catecholamine concentrations that are qualitatively different from reuptake inhibition; the ADHD versus neurotypical difference reflects different DAT densities in the striatum -- ADHD patients have increased DAT expression (measured by PET imaging), so methylphenidate must achieve higher synaptic dopamine levels before clinical effects occur.
• E) Methylphenidate is pharmacologically inert and produces its cognitive effects through expectation and placebo mechanisms -- the well-documented improvement in ADHD symptoms is primarily explained by the positive expectation created by the medical framing of the diagnosis and treatment; in neurotypical college students, methylphenidate's perceived cognitive enhancement is also placebo-mediated; the identical placebo effect in both populations explains why blinded studies frequently fail to demonstrate objective cognitive differences between methylphenidate and placebo in neurotypical adults.

4. A 67-year-old woman with myasthenia gravis (generalized, AChR-antibody positive, on pyridostigmine 60 mg four times daily) is admitted with worsening dysphagia and proximal arm weakness over 48 hours. She also has a UTI being treated with ciprofloxacin, started 3 days ago. On examination she has bilateral ptosis, nasal voice, neck flexor weakness (3/5), and proximal arm weakness (3/5). She denies fasciculations. Which of the following most accurately distinguishes myasthenic crisis from cholinergic crisis in this patient, explains why ciprofloxacin is relevant, and identifies the correct immediate management?

• A) This patient is in cholinergic crisis from pyridostigmine overdose -- the 3-day temporal correlation with ciprofloxacin introduction is irrelevant since fluoroquinolones have no interaction with AChE inhibitors; the diagnosis of cholinergic crisis is confirmed by the absence of muscarinic symptoms (no SLUDGE, no bradycardia, no bronchorrhea) described in the case -- in genuine cholinergic crisis, nicotinic NM symptoms (weakness from depolarizing block) always co-occur with prominent muscarinic symptoms; the appropriate management is to hold pyridostigmine, administer IV atropine for muscarinic symptoms, and provide ventilatory support.
• B) The clinical picture -- worsening MG weakness without fasciculations, without SLUDGE symptoms, in the setting of a new medication (ciprofloxacin) -- is most consistent with myasthenic crisis precipitated by fluoroquinolone-induced NMJ dysfunction; fluoroquinolones are recognized NMJ blocking drugs that impair presynaptic calcium channel function (reducing ACh release) and may have direct postsynaptic NM receptor blocking properties -- they are contraindicated or used with extreme caution in MG; the absence of fasciculations argues against cholinergic crisis (excess ACh at NM receptors would produce fasciculations before progressing to depolarizing block); immediate management: hold ciprofloxacin, continue or cautiously adjust pyridostigmine, urgent respiratory function assessment (negative inspiratory force, vital capacity), ICU admission, and consideration of plasma exchange or IVIG for the underlying MG exacerbation.
• C) This presentation is most consistent with myasthenic crisis precipitated by ciprofloxacin -- fluoroquinolones impair NMJ transmission through multiple mechanisms (presynaptic calcium channel blockade reducing ACh release, and direct nicotinic receptor channel block), and this drug class is listed among agents that can precipitate myasthenic crisis or worsen MG; the critical distinguishing features from cholinergic crisis are: (1) absence of fasciculations (cholinergic crisis produces fasciculations from NM depolarization before weakness); (2) absence of muscarinic signs (cholinergic crisis produces SLUDGE -- salivation, lacrimation, urination, defecation, GI cramps, emesis -- plus bradycardia and miosis); immediate management: stop ciprofloxacin; assess respiratory function urgently (bedside spirometry -- NIF and FVC); if NIF less than minus 20 to minus 25 cmH2O or FVC less than 1 L, elective intubation before respiratory failure; consider plasma exchange or IVIG to shorten myasthenic crisis duration; choose alternative antibiotic (avoid fluoroquinolones, aminoglycosides, and macrolides in MG).
• D) The absence of fasciculations and SLUDGE symptoms and the clear temporal relationship with ciprofloxacin introduction make myasthenic crisis (from fluoroquinolone NMJ blockade) the most likely diagnosis -- however, the edrophonium (Tensilon) test should be performed immediately at the bedside to definitively distinguish myasthenic from cholinergic crisis before any further management; a positive edrophonium test (transient improvement in ptosis or grip strength within 1-2 minutes of 2-10 mg IV edrophonium) confirms myasthenic crisis and guides continued pyridostigmine use; a negative or worsening response confirms cholinergic crisis and mandates pyridostigmine hold; the edrophonium test is safe to perform without atropine premedication in patients without cardiac disease.
• E) Ciprofloxacin inhibits pyridostigmine metabolism by blocking CYP1A2, causing pyridostigmine blood levels to rise to toxic concentrations over 3 days -- the clinical picture represents pyridostigmine toxicity (cholinergic crisis) from drug-drug interaction rather than myasthenic crisis; the appropriate management is to hold pyridostigmine, allow ciprofloxacin levels to fall (CYP1A2 inhibition reverses within 24 hours of ciprofloxacin discontinuation), and restart pyridostigmine at a lower dose; the UTI should be treated with an alternative antibiotic that does not inhibit CYP1A2.